Clinical trials: Non-proliferative Diabetic Retinopathy
Diabetic Retinopathy, Non Proliferative Diabetic Retinopathy
Randomized, Controlled Study to Investigate the 12-month Efficacy and Safety of Resveratrol Vitamin Supplements in Patients With Non-proliferative Diabetic Retinopathy Without Center Involved Diabetic Macular Edema (REVOLUTION Study)
This randomized, controlled study aims to investigate the efficacy and safety of resveratrol-containing vitamin supplements in patients with non-proliferative diabetic retinopathy (NPDR) without center-involved diabetic macular…
- Conditions
- Diabetic Retinopathy, Non Proliferative Diabetic Retinopathy, Prospective Study
- Trial name
- REVOLUTION (NCT07868458)
- Testing
- Resveratrol-Containing Vitamin Supplement
- Where
- Greece
- Volunteers
- 100 people
- Sponsor
- University of Athens
Non-center Involved Diabetic Macular Edema, Non-center Involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy
Study of INV-102 Ophthalmic Solution in Adults With Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy
Phase 2 study to assess the efficacy of topically administered eyedrops of INV-102 during a 12-week dosing period in subjects with non-center involved DME (NCIDME) associated with NPDR [Part 1] and during an 8-week dosing period…
- Conditions
- Non-center Involved Diabetic Macular Edema, Non-center Involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy, Diabetic Retinopathy, Center-involved Diabetic Macular Edema
- Trial name
- NCT06599684
- Testing
- INV-102
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Invirsa, Inc.
Diabetic Retinopathy, NPDR - Non Proliferative Diabetic Retinopathy
A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01
The goal of this clinical trial is to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of VX-01 as stand-alone treatment for Diabetic Retinopathy of Non-Proliferative Type (NPDR).
- Trial name
- NCT06770933
- Testing
- VX-01
- Where
- 27 sites in United States, Australia and 3 more
- Volunteers
- 100 people
- Sponsor
- Vantage Biosciences Ltd
Non-proliferative Diabetic Retinopathy (NPDR), Open-angle Glaucoma (OAG)
Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation
Pilot, single-site, prospective study of QLS-111 0.015 % in subjects with NPDR, OAG or NTG
- Conditions
- Non-proliferative Diabetic Retinopathy (NPDR), Open-angle Glaucoma (OAG), Normal Tension Glaucoma (NTG)
- Trial name
- (PENGUIN) (NCT07354477)
- Testing
- QLS-111 Ophthalmic Solution (0.015%), QLS-111 Ophthalmic Solution (0.075%)
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Qlaris Bio, Inc.
Non-Proliferative Diabetic Retinopathy
To Evaluate the Efficacy and Safety of Combination Therapy With B55R1 and B55R2 Compared to B55R1 Monotherapy in Patients With NPDR
This study is planned to evaluate the efficacy and safety of combination therapy with B55R1 and B55R2 compared to B55R1 monotherapy in patients with non-proliferative diabetic retinopathy (NPDR).
- Trial name
- NCT07230184
- Testing
- B55R1 and B55R2
- Where
- South Korea
- Volunteers
- 53 people
- Sponsor
- AJU Pharm Co., Ltd.
Diabetic Retinopathy, Diabetic Macular Edema
Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy
The objective of this study is to evaluate the safety and efficacy of APX3330 to treat diabetic retinopathy (DR) and diabetic macular edema (DME).
- Conditions
- Diabetic Retinopathy, Diabetic Macular Edema, NPDR - Non Proliferative Diabetic Retinopathy, PDR - Proliferative Diabetic Retinopathy
- Trial name
- ZETA-1 (NCT04692688)
- Testing
- APX3330
- Where
- 24 sites in United States
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Opus Genetics, Inc
Non-Proliferative Diabetic Retinopathy
Safety and Efficacy of Faricimab in Patients With NPDR
The purpose of this Phase 2 study is comprised of two groups to evaluate the safety, tolerability, and efficacy of faricimab in patients with Non-Proliferative Diabetic Retinopathy.
- Trial name
- MAGIC (NCT05681884)
- Testing
- Faricimab
- Where
- 16 sites in United States
- Volunteers
- 179 people
- Sponsor
- Greater Houston Retina Research
Non-Proliferative Diabetic Retinopathy
A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy
The purpose of this trial is to study the safety and effectiveness of OTX-TKI (axitinib intravitreal hydrogel) for the treatment of Non-Proliferative Diabetic Retinopathy.
- Trial name
- HELIOS-3 (NCT07235085)
- Testing
- Intravitreal injection of axitinib hydrogel implant followed by a second intravitreal injection of the axitinib implant at Week 24
- Where
- United States
- Volunteers
- 930 people
- Sponsor
- Ocular Therapeutix, Inc.
NPDR - Non Proliferative Diabetic Retinopathy, Diabetes Mellitus, Type 2
Characterization of Retinal Disease Progression in Eyes With Non Proliferative Diabetic Retinopathy in Diabetes Type 2 Using Non-invasive Procedures (CHART)
To identify biomarkers, obtained using non-invasive procedures, that can predict disease progression and progression to sight-threatening stages of the disease and to characterize the retinal changes that occur in Non…
- Conditions
- NPDR - Non Proliferative Diabetic Retinopathy, Diabetes Mellitus, Type 2, Retinal Disease
- Trial name
- CHART (NCT04636307)
- Testing
- Biomarkers
- Where
- 5 sites in France, Italy and 1 more
- Volunteers
- 202 people
- Sponsor
- Association for Innovation and Biomedical Research on Light and Image
Non-Proliferative Diabetic Retinopathy, Retinal Vein Occlusion
Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Diabetic Retinopathy or Retinal Vein Occlusion
The goal of this clinical trial is to learn about the safety of the investigational medicinal product ANXV. It will also learn about how ANXV works to treat non-proliferative diabetic retinopathy and retinal vein occlusion in…
- Trial name
- NEXUS (NCT07259928)
- Testing
- ANXV
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- Annexin Pharmaceuticals AB
Non-proliferative Diabetic Retinopathy (NPDR)
Efficacy and Safety of Ginkgo Biloba Extract EGb761® in Patients With Diabetic Retinopathy
This study is a single-center, open-label, parallel-controlled trial, scheduled to commence in October 2025 at the outpatient and inpatient departments of Shanghai General Hospital.
- Trial name
- NCT07236645
- Testing
- Ginaton (ginkgo biloba extract tablet), standard treatment
- Volunteers
- 200 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Non-proliferative Diabetic Retinopathy (NPDR), Diabetic Retinal Microangiopathy
A Preliminary Exploratory Clinical Trial to Evaluate the Efficacy of NPDR-01 Eye Drops in the Treatment of Non-Proliferative Diabetic Retinopathy
This study aims to explore the preliminary clinical efficacy and safety of NPDR-01 eye drops in patients with non-proliferative diabetic retinopathy (NPDR).
- Conditions
- Non-proliferative Diabetic Retinopathy (NPDR), Diabetic Retinal Microangiopathy, Retinal Microaneurysms, Diabetic Retinopathy
- Trial name
- NCT07198815
- Testing
- Investigational Eye Drops (NPDR-01)
- Volunteers
- 10 people
- Sponsor
- Sichuan Academy of Medical Sciences
Non-Proliferative Diabetic Retinopathy
Clinical Study on the Efficacy and Safety of TNTL in the Treatment of Non-proliferative Diabetic Retinopathy
The goal of this clinical trial is to learn if drug TNTL works to treat non-proliferative diabetic retinopathy in adults. It will also learn about the safety of drug TNTL. The main questions it aims to answer are: 1.
- Trial name
- TNTL (NCT06817265)
- Testing
- TNTL, TNTL simulation preparation
- Where
- 30 sites in China
- Volunteers
- 360 people
- Sponsor
- Beletalent (Zhuhai) Pharmaceutical Co., Ltd
Diabetic Retinopathy, Non-Proliferative Diabetic Retinopathy
Remote Ischemic Conditioning for Non-Proliferative Diabetic Retinopathy
The goal of this clinical trial is to evaluate whether remote ischemic conditioning (RIC) is a safe and effective treatment for non-proliferative diabetic retinopathy (NPDR) in adults aged 40-80 years with type 2 diabetes.
- Conditions
- Diabetic Retinopathy, Non-Proliferative Diabetic Retinopathy, Remote Ischemic Conditioning, Diabetes Mellitus, Type 2
- Trial name
- RIC-NPDR (NCT06713720)
- Testing
- Remote Ischemic Conditioning Device
- Where
- 2 sites in China
- Volunteers
- 68 people
- Sponsor
- Xuxiang Zhang, MD
Non-Proliferative Diabetic Retinopathy
Intravitreal and Intracameral DEX in NPDR
To investigate the effects of intravitreal and intracameral injection of dexamethasone during cataract phacoemulsification in patients with mild to moderate non-proliferative diabetic retinopathy
- Trial name
- NCT06951087
- Testing
- Dexamethasone sodium phosphate
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Affiliated Hospital of Nantong University
Chronic Kidney Disease, Non-proliferative Diabetic Retinopathy
A Study to Learn How Safe BAY3283142 is When Taken as a Single Dose or as Multiple Doses in Healthy Chinese Participants
Researchers are looking for a better way to treat people who have chronic kidney disease (CKD) or non-proliferative diabetes retinopathy (NPDR).
- Conditions
- Chronic Kidney Disease, Non-proliferative Diabetic Retinopathy, Healthy Volunteers
- Trial name
- NCT06487845
- Testing
- BAY3283142
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Bayer
Non-proliferative Diabetic Retinopathy
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR)
This Phase 3 Study will evaluate the efficacy and safety of KSI-301 in participants with moderately severe to severe non-proliferative diabetic retinopathy (NPDR).
- Trial name
- GLOW (NCT05066230)
- Testing
- KSI-301
- Where
- 61 sites in United States, Czechia and 5 more
- Volunteers
- 253 people
- Sponsor
- Kodiak Sciences Inc
Non-proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy
Phase 2 Spectra Study to Evaluate the Safety and Efficacy of OPL-0401 in Patients With Diabetic Retinopathy
OPL-0401-201 is a multicenter study to investigate the safety and efficacy of OPL-0401 in patients with diabetes mellitus (DM) with diabetic retinopathy.
- Trial name
- NCT05393284
- Testing
- OPL-0401 Dose 1
- Where
- 25 sites in United States
- Volunteers
- 114 people
- Sponsor
- Valo Health, Inc.
Non Proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy
Changes in Electroretinogram and Contrast Sensitivity After PASCAL Treatment
Laser photocoagulation has become the treatment of choice in PDR. Laser photocoagulation has become the treatment of choice in PDR.
- Trial name
- NCT00563043
- Testing
- PASCAL laser treatment
- Where
- Mexico
- Volunteers
- 8 people
- Sponsor
- Asociación para Evitar la Ceguera en México
Non Proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy
Changes in Macular Thickness After Patterns Scan Laser
Laser photocoagulation has become the treatment of choice in PDR. Laser photocoagulation has become the treatment of choice in TMD.
- Trial name
- NCT00563628
- Testing
- Panretinal photocoagulation with PASCAL system
- Where
- Mexico
- Volunteers
- 8 people
- Sponsor
- Asociación para Evitar la Ceguera en México